Recent modeling analysis estimated that combination therapy with an SGLT-2 inhibitor, a GLP-1 receptor agonist, and finerenone in patients with type 2 diabetes and albuminuria could reduce the risk of major adverse cardiovascular events by 35% (HR, 0.65; 95% CI, 0.55 to 0.76), hospitalization for heart failure by 55% (HR, 0.45; 95% CI, 0.34 to 0.58), and CKD progression by 36% (HR, 0.42; 95% CI, 0.51 to 0.80), compared with conventional care (94). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.